Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

9 ( 1 )

2019 ( 149 )

2018 ( 201 )

2017 ( 224 )

Custom range...

Search Results: 1 - 10 of 18502 matches for " Khamesipour Ali "
All listed articles are free for downloading (OA Articles)
Page 1 /18502
Display every page Item
Dermatology eponyms – phenomen / sign – Lexicon (D)
Brzeziński Piotr,Wollina Uwe,Pokl?kowska Katarzyna,Khamesipour Ali
Our Dermatology Online , 2011,
Effect of Leishmania gerbilli Injection on Mice Immunization Against Cutaneous Leishmaniasis (CL) Caused by Leishmania major
Abedi Said,Khamesipour Ali,Izadi Shahrokh,Hejazi Hosein
Pakistan Journal of Biological Sciences , 2007,
Abstract: In the present study Leishmania gerbilli were used to immunize BALB/c mice against pathogenic strains of leishmania to determine whether injection of L. gerbilli in mice could protect them against later L. major inoculation. Eighty female BALB/c mice were divided by random in eight groups. Promastigotes of L. major and L. gerbilli were used. Mice were inoculated with three different doses of L. gerbilli (3x106, 2x107 and 5x107) via subcutaneous (SC) in the base of their tails or interpretoen (IP). Forty days after the first injection, all mice received the same doses as a booster. Two control groups received PBS (SC or IP) only. All BALB/c mice were inoculated subcutaneously with 2x106. Promastigotes of L. major in the base of their tails after 75 days of the first injection of L. gerbilli. When leishmania lesion developed (35 days after challenge), the size was measured and continued once a week for 12 weeks. Meanwhile, the liver and spleen samples of dead mice moved to culture media and examined for the parasite. Delaed Type Hypersensitivity (DTH) and immunoflurecent tests were used to determine results of immunization. Compared with the control group and the other groups that received different doses of L. gerbilli via IP, an evident decrease in lesion size was observed in group that received 2x107 promastigotes (p<0.05). By contrast, in those groups received L. gerbilli subcutaneously, no difference was observed through the different doses of inoculated parasite. Comparison of the inoculation styles showed that IP method caused smaller lesions than SC (p<0.05).
Comparison of efficacy of intralesional injection of meglumine anti-moniate once-weekly with twice-weekly in the treatment of anthroponotic cutaneous leishmaniasis in Mashhad: a randomized clinical trial
Ali Khamesipour,Mohammad Hossein Ghoorchi,Alireza Khatami,Seyed Ebrahim Eskandari
Dermatology and Cosmetic , 2011,
Abstract: Background and Aim: Cutaneous leishmaniasis (CL) is endemic in Iran, where it is one of the most important health problems. Both anthroponotic CL (ACL) caused by L. tropica and zoonotic CL (ZCL) caused by L. major are reported. Antimoniate derivatives as the standard therapy for CL need multiple injections and are not easy to tolerate for the patients. This study was conducted in Mashhad to compare the efficacy of weekly versus twice a week intralesional injections of meglumine antimoniate (MA) in the treatment of ACL."n"nMethods: This randomised controlled trial was performed during 2006 to 2008 in Mashhad, Iran. Using computerized sequence of random numbers, participants were randomly allocated in the two arms of the study: one receiving weekly and the other receiving twice-a-week intralesional injections of MA. The lesion size, induration and healing rate were assessed, recorded and compared. Healing was defined as complete re-epithelialisation and disappearance of induration."n"nResults: A total of 252 suspected CL patients with 372 lesions were screened. 82 parasitologically proven cases with 121 lesions caused by L. tropica were included and 74 patients with 113 lesions completed the study. At 12th week after initiation of treatment, complete healing was observed in 38 out of 44 lesions (86.4%) in the group which received weekly intralesional MA injection. The median time-to-heal in this group was 36 days (95% confidence interval [CI]: 32.0-39.9). Complete healing was recorded in 60 out of 69 lesions (86.9%) in the group which received twice a week intralesional injections of MA with a median time-to-heal of 25 days (95% CI: 20.9-29.1). While no significant difference was observed between the two groups in terms of complete healing rate (P=0.999), time-to-heal was significantly different between the 2 groups (P=0.003)."n"nConclusion: It seems that the effectiveness of twice-weekly intralesional injections of MA is similar to once-weekly regimen while the former regimen causes more rapid healing of lesions.
Comparison of the efficacy of weekly vs. twice a week intralesional injections of meglumine antimoniate in the treatment of anthroponotic cutaneous leishmaniasis: a randomized clinical trial
Ali Khamesipour,Alireza Khatami,Iraj Sharifi,Mahdie Bahrami
Dermatology and Cosmetic , 2010,
Abstract: "nBackground and Aim: Treatment of cutaneous leishmaniasis, especially when caused by L. tropica, is challenging. Meglumine antimoniate (Glucantime ) is used as the standard treatment, but multiple injectiond are necessary. The objective of this study was to compare the efficacy of weekly intralesional injections with twice weekly injections of Glucantime for the treatment of anthroponotic cutaneous leishmaniasis (ACL)."n"nMethods: This randomized open clinical trial was conducted, in Bam, Kerman province, Iran. 96 eligible patients according to inclusion and exclusion criteria who were willing to participate were included. The included patients were randomly assigned into two groups, one group treated with weekly intralesional injections of Glucantime and the other group treated with intralesional Glucantime twice a week. Type and size of each lesion (induration, ulcer and scar) were recorded weekly. Complete healing was defined as complete re-epithelialization and absence of induration in all lesions and was considered as the primary outcome measure."n"nResults: A total of 48 patients completed the study; complete cure was seen in 24 of 27 (89%) patients who received weekly intralesional MA with a mean duration of healing equals to 70±10 days. Complete cure was seen in 24 of 31 (77%) patients who received intralesional MA twice a week, the mean duration of healing in the latter group was 58±5 days. There was no significant difference between the two groups (P=0.23)."n"nConclusion: It seems that the efficacy of intralesional injections of Glucantime once a week is similar to efficacy of twice a week Glucantime injections.
Identification of Malassezia species associated with pityriasis versicolor using PCR-RFLP
Mahnaz Mahmoudi Rad,Akram Miramin Mohammadi,Parviz Tousi,Ali Khamesipour
Dermatology and Cosmetic , 2011,
Abstract: "nBackground and Aim: Malassezia is a lipophilic and dimorphic fungus which has different species. Some of them can be found as natural flora on skin and in some conditions may cause pityriasis versicolor. The aim of this study was to identify Malassezia species associated with pityriasis versicolor in Iranian patients, using PCR-RFLP."n"nMethods: In this study out of 65 patients with pityriasis versicolor to have pityriasis versicolor,isolates of 60 patients were positive. Malassezia species. using by PCR-RFLP. The Internal Transcribed Spacer 2 (ITS2) region was amplified by PCR employing the ITS3 and ITS4 primers and The restriction endonucleases AluI, BanI and MspAI were selected for producing distinct RFLP patterns."n"nResults: M. furfur (36.7%), M. globosa (30.0%), M. sympodialis (20.0%), M. slooffiae (8.3%), M. restricta (3.3%) and M. obtusa (1.7%) were the microorganisms responsible for the infection among participants. The M. sympodialis infection was strongly correlated with the female gender (P=0.02)."n"nConclusion: Our findings suggest that, the most common Malassezia species associated with pityriasis versicolor was M. furfur, followed by M. globosa.
Phenotyping of peripheral memory T cell subsets in cutaneous leishmaniasis
Ali Khamesipour,Mahmoud Nateghi Rostami,Hossein Keshavarz,Akram Miramin Mohammadi
Dermatology and Cosmetic , 2010,
Abstract: "nBackground and Aim: The heterogenous population of memory T lymphocytes is distinguished based on surface markers and effector functions such as cytokine secretion. Recently, two subsets of memory T cells are defined by expression of chemokine receptor CCR7 and CD45RA designating as "central memory" T cells (TCM) and "effector memory" T cells (TEM). The objective of this staudy was to evaluate the phenotype and function of these lymphocytes in healed cases of cutaneous leishmaniasis."n"nMethods: The phenotype of lymphocytes were determined in blood samples of 13 volunteers with history of self healing cutaneous leishmaniasis (HCL) and in 6 healthy controls."n"nResults: No significant difference was found in memory T cell subsets between HCL volunteers and healthy controls using flow cytometry. However, following sorting of different memory subsets, a significantly higher proliferation was seen in cells of HCL volunteers comparing to the control group. A significantly higher IFN-γ response in TEM and a significantly higher IL-2 response in TCM were observed in cell culture of HCL volunteers comparing controls."n"nConclusion: The responses were elicited when the cells were stimulate with SLA in vitro, it is concluded Leishmania-specific TEM and Leishmania-specific TCM subsets exist in HCL volunteers and since the volunteers with history of CL presumed to be protected against reinfection, it seems that both TCM and TEM play role in the protection against Leishmania infection in these individuals.
A Dual Drug Sensitive L. major Induces Protection without Lesion in C57BL/6 Mice
Noushin Davoudi ,Ali Khamesipour ,Fereidoun Mahboudi,W. Robert McMaster
PLOS Neglected Tropical Diseases , 2014, DOI: 10.1371/journal.pntd.0002785
Abstract: Leishmaniasis is a major health problem in some endemic areas and yet, no vaccine is available against any form of the disease. Historically, leishmanization (LZ) which is an inoculation of individual with live Leishmania, is the most effective control measure at least against cutaneous leishmaniasis (CL). Due to various reasons, LZ is not used today. Several live attenuated Leishmania have been developed but their use is limited. Previously, we developed a transgenic strain of L. major that harbors two suicide genes tk and cd genes (lmtkcd+/+) for use as a challenge strain in vaccine studies. These genes render the parasite susceptible to Ganciclovir (GCV) and 5-flurocytosine (5-FC). The dual drug sensitive strain of L. major was developed using gene targeting technology using a modified Herpes Simplex Virus thymidine kinase gene (hsv-tk) sensitive to Ganciclovir antibiotic and Saccharomyces cerevisae cytosine deaminase gene (cd sensitive to 5-flurocytosine) that were stably introduced into L. major chromosome. BALB/c mice inoculated with lmtkcd+/+ developed lesions which upon treatment with GCV and 5-FC completely healed. In the current study, the transgenic lmtkcd+/+strain was assessed as a live vaccine model to determine the time necessary to develop a protective immune response. C57BL/6 mice were inoculated with the transgenic lmtkcd+/+strain, and treated at the time of inoculation (day0) or at day 8 after inoculation. Immunized animals were challenged with wild-type L. major, and complete protection was induced in mice that were treated at day 8. The results show that in contrast to leishmanization, in group of mice inoculated with a dual sensitive L. major development and persistence of lesion is not necessary to induce Th1 response and protection.
CD8+ T Cells as a Source of IFN-γ Production in Human Cutaneous Leishmaniasis
Mahmoud Nateghi Rostami,Hossein Keshavarz,Rosita Edalat,Abdolfattah Sarrafnejad,Tahereh Shahrestani,Fereidoun Mahboudi,Ali Khamesipour
PLOS Neglected Tropical Diseases , 2010, DOI: 10.1371/journal.pntd.0000845
Abstract: Background In human leishmaniasis Th1/Th2 dichotomy similar to murine model is not clearly defined and surrogate marker(s) of protection is not yet known. In this study, Th1/Th2 cytokines (IL-5, IL-10, IL-13 and IFN-γ) profile induced by purified CD4+/CD8+ T cells in response to Leishmania antigens were assessed at transcript and protein levels in 14 volunteers with a history of self-healing cutaneous leishmaniasis (HCL) and compared with 18 healthy control volunteers. Methodology/Principal Findings CD4+/CD8+/CD14+ cells were purified from peripheral blood using magnetic beads; CD4+/CD8+ T cells were co-cultured with autologous CD14+ monocytes in the presence of soluble Leishmania antigens (SLA). Stimulation of either CD4+ T cells or CD8+ T cells of HCL volunteers with SLA induced a significantly (P<0.05) higher IFN-γ production compared with the cells of controls. Upregulation of IFN-γ gene expression in CD4+ cells (P<0.001) and CD8+ cells (P = 0.006) of HCL volunteers was significantly more than that of controls. Significantly (P<0.05) higher fold-expression of IFN-γ gene was seen in CD4+ cells than in CD8+ cells. In HCL volunteers a significantly (P = 0.014) higher number of CD4+ cells were positive for intracellular IFN-γ production than CD8+ cells. Conclusions/Significance Collectively, the volunteers have shown maintenance of specific long-term immune responses characterized by a strong reaction to leishmanin skin test and IFN-γ production. The dominant IFN-γ response was the result of expansion of both CD4+ and CD8+ T cells. The results suggested that immune response in protected individuals with a history of zoonotic cutaneous leishmaniasis (ZCL) due to L. major is mediated not only through the expansion of antigen-specific IFN-γ producing CD4+ Th1 cells, but also through IFN-γ producing CD8+ T cells.
Unresponsiveness to Glucantime Treatment in Iranian Cutaneous Leishmaniasis due to Drug-Resistant Leishmania tropica Parasites
Ramtin Hadighi,Mehdi Mohebali ,Patrick Boucher,Homa Hajjaran,Ali Khamesipour,Marc Ouellette
PLOS Medicine , 2006, DOI: 10.1371/journal.pmed.0030162
Abstract: Background Recent circumstantial evidence suggests that an increasing number of Iranian patients with cutaneous leishmaniasis are unresponsive to meglumine antimoniate (Glucantime), the first line of treatment in Iran. This study was designed to determine whether the clinical responses (healing, or non-healing) were correlated with the susceptibility of Leishmania parasites to Glucantime. Methods and Findings In vitro susceptibility testing was first performed on 185 isolated parasites in the intracellular mouse peritoneal macrophage model. A strong correlation between the clinical outcome and the in vitro effective concentration 50% (EC50) values was observed. Parasites derived from patients with non-healing lesions had EC50 values at least 4-fold higher than parasites derived from lesions of healing patients. A selection of these strains was typed at the molecular level by pulsed-field gels and by sequencing the pteridine reductase 1 (PTR1) gene. These techniques indicated that 28 out of 31 selected strains were Leishmania tropica and that three were Leishmania major. The L. major isolates were part of a distinct pulsed-field group, and the L. tropica isolates could be classified in three related additional pulsed-field groups. For each pulsed-field karyotype, we selected sensitive and resistant parasites in which we transfected the firefly luciferase marker to assess further the in vitro susceptibility of field isolates in the monocyte cell line THP1. These determinations confirmed unequivocally that patients with non-healing lesions were infected with L. tropica parasites resistant to Glucantime. Additional characterization of the resistant isolates showed that resistance is stable and can be reversed by buthionine sulfoximine, an inhibitor of glutathione biosynthesis. Conclusions To the authors' knowledge, this is the first report of proven resistant parasites contributing to treatment failure for cutaneous leishmaniasis and shows that primary Glucantime-resistant L. tropica field isolates are now frequent in Iran.
Dressings Combined with Injection of Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial
Alireza Khatami, Rezvan Talaee, Makan Rahshenas, Ali Khamesipour, Pedram Mehryan, Sepideh Tehrani, Yahya Dowlati, Alireza Firooz
PLOS ONE , 2013, DOI: 10.1371/journal.pone.0066123
Abstract: Background Cutaneous leishmaniasis (CL) is a neglected infectious disease and a major health problem in several developing countries. Despite some reasonable explanation for their potential benefits, there is only trace evidence regarding the role of dressings in the treatment of CL. Methods This randomized, assessor-blind, controlled, clinical trial was conducted in an endemic area for CL caused by Leishmania major in Iran to assess the efficacy of administration of weekly intralesional meglumine antimoniate (i.l.MA) either alone or combined with application of a silver or a non-silver polyester dressing on their lesions for 6 weeks. After screening of 241 patients with CL lesions, 83 eligible patients with 158 lesions were randomly allocated in three arms of the study. Eligibility criteria included parasitologically confirmed CL, age of 12 to 60 years; willingness to participate, duration of lesion<3 months, number of lesions<5, largest ulcer diameter<5 cm. Pregnant or lactating women were excluded. The primary outcome was absolute risk reduction (ARR) based on the proportion of complete healing, which was defined as more than 75% reduction in the size of the lesion compared with baseline in each group at the termination of treatment and 1 month later. Findings ARR (95% Confidence Interval [CI]) in i.l.MA versus i.l.MA+non-silver dressing groups was 5.98% (?7.07% to 20.25%), between i.l.MA versus i.l.MA+silver dressing groups was ?0.23% (?13.53% to 14.82%), and between i.l.MA+non-silver dressing versus i.l.MA+silver dressing groups was ?6.21%(?18.28% to 6.52%) after 6 weeks of treatment. ARR (95% CI) in i.l.MA versus i.l.MA+non-silver dressing groups was ?2.22% (?22.12% to 18.10%), between i.l.MA versus i.l.MA+silver dressing groups was 3.64% (?15.36% to 22.82%), and between i.l.MA+non-silver dressing versus i.l.MA+silver dressing groups was 5.86% (?12.86% to 24.31%) 1 month later. Conclusion It could not be demonstrated that the efficacy of i.l.MA was improved by either dressing. Trial Registration Iranian Registry of Clinical Trials (IRCT.ir) IRCT138707201166N2.
Page 1 /18502
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.